Summary & Overview
HCPCS Level II C9068: Copper Cu-64 dotatate, Diagnostic, 1 millicurie
HCPCS Level II code C9068 denotes Copper Cu-64 dotatate, a diagnostic radiopharmaceutical typically supplied in a 1 millicurie dosage for imaging somatostatin receptor–positive tissues. This agent is used in nuclear medicine studies to aid in detection and localization of certain neuroendocrine and somatostatin receptor–expressing tumors, making the code relevant for imaging departments, oncology practices, and payers monitoring specialty radiopharmaceutical utilization.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context and typical sites of service, along with payer coverage patterns, coding considerations, and benchmarking topics relevant to radiopharmaceuticals. The publication summarizes what providers and billing professionals need to know about HCPCS Level II code C9068, including common claims considerations and areas where payers often have specific documentation or prior authorization requirements.
The report offers concise benchmarks and policy update highlights where available, practical coding context for service lines that bill nuclear medicine procedures, and pointers on typical billing pathways for diagnostic radiopharmaceuticals. Data not available in the input.
Billing Code Overview
HCPCS Level II code C9068 describes Copper Cu-64 dotatate, diagnostic, 1 millicurie. This code represents a radiopharmaceutical diagnostic agent used in nuclear medicine imaging to visualize somatostatin receptor–expressing tissues.
Service Type: Diagnostic radiopharmaceutical administration
Typical Site of Service: Hospital outpatient imaging department, hospital-based nuclear medicine, and freestanding imaging centers
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred for functional imaging to localize somatostatin receptor–expressing neuroendocrine tumors (NETs) or to evaluate suspected NET recurrence. The patient presents to a hospital outpatient nuclear medicine or radiopharmacy unit. Pre-procedure verification includes confirming indication, recent renal function, pregnancy status, and informed consent. A radiopharmacy prepares C9068 (Copper Cu-64 DOTATATE, diagnostic, 1 millicurie) under sterile conditions and performs quality control and radiolabeling checks. The patient arrives fasting per local protocol, IV access is established, and baseline vital signs are recorded. The radiotracer C9068 is administered intravenously; the patient typically rests for an uptake period (per local protocol, often about 60–90 minutes). After uptake, the patient undergoes PET/CT imaging to acquire whole-body images from skull base to mid-thigh (or adjusted field of view) to identify somatostatin receptor–positive lesions. Post-procedure monitoring is brief; the radiology or nuclear medicine physician interprets the images and issues a diagnostic report documenting findings and comparison to prior studies when available. Billing uses C9068 for the radiopharmaceutical dose; associated PET/CT technical and professional components are billed separately using appropriate CPT codes and modifiers as clinically applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|